|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CA3093606A1
(en)
|
2013-03-15 |
2014-09-18 |
Xencor, Inc. |
Heterodimeric proteins for induction of t cells
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
PE20160953A1
(es)
|
2013-12-12 |
2016-09-26 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
|
|
ES2923641T3
(es)
*
|
2013-12-30 |
2022-09-29 |
Epimab Biotherapeutics Inc |
Inmunoglobulina con Fabs en tándem y usos de la misma
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
ES3040431T3
(en)
|
2014-03-12 |
2025-10-31 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
CA2944647C
(en)
|
2014-04-03 |
2025-07-08 |
Igm Biosciences Inc |
MODIFIED J STRING
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
CN106999585A
(zh)
*
|
2014-09-28 |
2017-08-01 |
加利福尼亚大学董事会 |
对刺激性和非刺激性骨髓细胞的调节
|
|
SG11201703403TA
(en)
|
2014-10-27 |
2017-05-30 |
Agency Science Tech & Res |
Anti-tim-3 antibodies
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
DK3221363T3
(da)
|
2014-11-21 |
2020-08-10 |
Bristol Myers Squibb Co |
Antistoffer mod cd73 og anvendelser deraf
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
|
US10689449B2
(en)
|
2015-01-20 |
2020-06-23 |
Igm Biosciences, Inc. |
Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
|
|
IL297997A
(en)
|
2015-03-04 |
2023-01-01 |
Igm Biosciences Inc |
Cd20 binding molecules and uses thereof
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
MX2017011644A
(es)
|
2015-03-13 |
2017-12-04 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
|
|
KR20180029201A
(ko)
|
2015-05-18 |
2018-03-20 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
|
|
CN111234027A
(zh)
|
2015-05-21 |
2020-06-05 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
|
EP3322732A2
(en)
|
2015-07-13 |
2018-05-23 |
Cytomx Therapeutics Inc. |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
|
WO2017009419A1
(en)
*
|
2015-07-16 |
2017-01-19 |
Ares Life Sciences S.A. |
Bispecific antibody-like molecules having bivalency vis-à-vis each antigen
|
|
CN116333138A
(zh)
|
2015-07-30 |
2023-06-27 |
宏观基因有限公司 |
Pd-1结合分子和其使用方法
|
|
US20180230431A1
(en)
*
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
|
HUE069387T2
(hu)
|
2015-09-30 |
2025-03-28 |
Igm Biosciences Inc |
Módosított J-lánccal rendelkezõ kötõmolekulák
|
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
CN107949574A
(zh)
*
|
2015-10-02 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
KR20180053674A
(ko)
|
2015-10-02 |
2018-05-23 |
에프. 호프만-라 로슈 아게 |
공자극 tnf 수용체에 특이적인 이중특이성 항체
|
|
KR20180085800A
(ko)
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
TW202208440A
(zh)
|
2015-12-14 |
2022-03-01 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
|
US20190241658A1
(en)
*
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
|
EP3408293A4
(en)
*
|
2016-01-28 |
2019-09-11 |
Janssen Biotech, Inc. |
BIS-SPECIFIC ANTI-TNF-ALPHA / IL-17A ANTIBODIES AND ANTI-TNF-ALPHA ANTIBODIES AND METHODS FOR THEIR USE
|
|
ES2924775T3
(es)
*
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos y composición farmacéutica para el tratamiento del cáncer
|
|
AU2017214692B2
(en)
|
2016-02-06 |
2021-11-04 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
WO2017189569A1
(en)
*
|
2016-04-25 |
2017-11-02 |
Trustees Of Tufts College |
Multimediator dpp4 and fap inhibitors, and uses related thereto
|
|
WO2017189805A1
(en)
|
2016-04-27 |
2017-11-02 |
Abbvie Inc. |
Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
|
|
GB2550114A
(en)
|
2016-05-03 |
2017-11-15 |
Kymab Ltd |
Methods, regimens, combinations & antagonists
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
BR112018073739A2
(pt)
|
2016-05-20 |
2019-02-26 |
Harpoon Therapeutics, Inc. |
proteína de ligação de albumina sérica de domínio único
|
|
CN109641046B
(zh)
|
2016-05-20 |
2023-11-07 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
KR101985299B1
(ko)
*
|
2016-06-03 |
2019-09-03 |
삼성전자주식회사 |
항-c-Met/항-Nrp1 이중 특이 항체
|
|
IL263542B2
(en)
*
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
BR112018076260A2
(pt)
|
2016-06-20 |
2019-03-26 |
Kymab Limited |
anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN116640214A
(zh)
|
2016-08-09 |
2023-08-25 |
科马布有限公司 |
分离抗体及其应用
|
|
NZ750001A
(en)
*
|
2016-08-16 |
2025-09-26 |
Epimab Biotherapeutics Inc |
Monovalent asymmetric tandem fab bispecific antibodies
|
|
JP7080219B2
(ja)
*
|
2016-08-30 |
2022-06-03 |
ゼンコア インコーポレイテッド |
共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
|
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
|
EP3515494A4
(en)
*
|
2016-09-26 |
2020-10-07 |
The Brigham and Women's Hospital, Inc. |
REGULATORS OF B-LYMPHOCYTES MEDIA IMMUNOSUPPRESSION
|
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
CN110214148A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原結合タンパク質
|
|
EP3551047A1
(en)
|
2016-12-07 |
2019-10-16 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
|
WO2018112256A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
|
TW201834711A
(zh)
|
2016-12-14 |
2018-10-01 |
美商寶珍那提公司 |
以tnf抑制劑治療胃腸道疾病
|
|
EP4190318A1
(en)
|
2016-12-14 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
|
|
CA3045310A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
|
CA3046019A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
|
JP7150723B2
(ja)
|
2016-12-14 |
2022-10-11 |
ビオラ・セラピューティクス・インコーポレイテッド |
消化管疾病のインテグリン阻害薬による治療
|
|
CA3046023A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
|
WO2018112232A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
|
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
|
US11680101B2
(en)
|
2017-01-27 |
2023-06-20 |
Kymab Limited |
Anti-OPG antibodies
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
AU2018244922A1
(en)
|
2017-03-30 |
2019-09-12 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
WO2018183934A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
|
US11596670B2
(en)
|
2017-03-30 |
2023-03-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
|
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
CA3063359A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
EP3630838A1
(en)
|
2017-06-01 |
2020-04-08 |
CytomX Therapeutics, Inc. |
Activatable anti-pdl1 antibodies, and methods of use thereof
|
|
CN111032085A
(zh)
*
|
2017-06-05 |
2020-04-17 |
昆士兰医学研究所理事会 |
用于癌症治疗或预防的免疫检查点分子拮抗剂和rank-l（nf-kb配体）拮抗剂的组合或其双特异性结合分子及其用途
|
|
EP3415527B1
(de)
|
2017-06-14 |
2025-12-10 |
Kymab Ltd. |
Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen
|
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
EP3652209A2
(en)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics LLC |
Agonist antibodies that bind human cd137 and uses thereof
|
|
IL271818B2
(en)
*
|
2017-07-21 |
2024-10-01 |
Trianni Inc |
Single chain vh and heavy chain antibodies
|
|
ES2963157T3
(es)
|
2017-07-26 |
2024-03-25 |
Forty Seven Inc |
Anticuerpos anti-SIRP-alfa y métodos relacionados
|
|
JP2020529605A
(ja)
|
2017-08-01 |
2020-10-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
濾過およびクロマトグラフィ用ポッドならびにその使用方法
|
|
US20200306516A1
(en)
|
2017-08-14 |
2020-10-01 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
|
|
EP3668893A4
(en)
*
|
2017-08-16 |
2021-08-04 |
Dragonfly Therapeutics, Inc. |
PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
|
|
WO2019042555A1
(en)
*
|
2017-08-31 |
2019-03-07 |
Humabs Biomed Sa |
MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
|
|
UA129446C2
(uk)
|
2017-10-13 |
2025-04-30 |
Гарпун Терап'Ютікс, Інк. |
Триспецифічні білки і способи їх застосування
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20190160102A1
(en)
|
2017-11-03 |
2019-05-30 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CN111712258B
(zh)
|
2017-12-12 |
2024-03-15 |
开拓免疫医疗公司 |
抗trem2抗体和相关方法
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
JP7653013B2
(ja)
|
2018-01-04 |
2025-03-28 |
アイコニック セラピューティクス リミテッド ライアビリティ カンパニー |
抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
|
|
US20190330591A1
(en)
|
2018-01-10 |
2019-10-31 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
JP2021512956A
(ja)
*
|
2018-02-06 |
2021-05-20 |
ザ ジェネラル ホスピタル コーポレイション |
腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
CA3090236A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
KR102832460B1
(ko)
|
2018-02-20 |
2025-07-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
|
|
MX394121B
(es)
|
2018-03-14 |
2025-03-24 |
Surface Oncology Inc |
Anticuerpos que se unen a cd39 y sus usos
|
|
US11780926B2
(en)
*
|
2018-03-22 |
2023-10-10 |
Universität Stuttgart |
Multivalent binding molecules
|
|
BR112020018918A2
(pt)
|
2018-03-22 |
2021-01-05 |
Surface Oncology, Inc. |
Anticorpos anti-il-27 e usos dos mesmos
|
|
MX2020010267A
(es)
*
|
2018-03-30 |
2020-11-06 |
Merus Nv |
Anticuerpo multivalente.
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
JP7368453B2
(ja)
*
|
2018-05-03 |
2023-10-24 |
シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド |
Ｐｄ－１およびｌａｇ－３に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
EP3806885A2
(en)
|
2018-06-13 |
2021-04-21 |
Kymab Limited |
Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
|
|
WO2019246317A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
WO2020010077A1
(en)
*
|
2018-07-03 |
2020-01-09 |
Ngm Biopharmaceuticals, Inc. |
Bispecific antibodies
|
|
TW202035447A
(zh)
*
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
MX2021001527A
(es)
|
2018-08-08 |
2021-06-15 |
Dragonfly Therapeutics Inc |
Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MA53293A
(fr)
|
2018-08-08 |
2021-11-17 |
Dragonfly Therapeutics Inc |
Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
EP3833443A1
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigen binding agents that bind cd277 and uses thereof
|
|
EP3833442A2
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antibodies that bind cd277 and uses thereof
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
GB201815629D0
(en)
|
2018-09-25 |
2018-11-07 |
Kymab Ltd |
Antagonists
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
KR20210096612A
(ko)
*
|
2018-10-29 |
2021-08-05 |
티가티엑스, 인크. |
IgA 항체 구축물을 포함하는 조성물 및 방법
|
|
AU2019372673A1
(en)
|
2018-11-01 |
2021-05-27 |
Gracell Biotechnologies (Shanghai) Co., Ltd. |
Compositions and methods for T cell engineering
|
|
CN109836502B
(zh)
*
|
2018-11-12 |
2021-09-07 |
浙江大学 |
一种双特异性抗体及其应用
|
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
|
CN113166258B
(zh)
*
|
2018-12-03 |
2023-06-20 |
宜明昂科生物医药技术（上海）股份有限公司 |
靶向pd-l1和vegf的重组蛋白
|
|
MA54469A
(fr)
|
2018-12-13 |
2021-10-20 |
Surface Oncology Inc |
Anticorps anti-il-27 et leurs utilisations
|
|
GB201820687D0
(en)
|
2018-12-19 |
2019-01-30 |
Kymab Ltd |
Antagonists
|
|
CA3123177A1
(en)
|
2018-12-21 |
2020-06-25 |
Kymab Limited |
Fixaxfx bispecific antibody with common light chain
|
|
MX2021007672A
(es)
|
2018-12-24 |
2021-09-30 |
Sanofi Sa |
Proteinas de union multiespecificas con dominios fab mutantes.
|
|
US20220111047A1
(en)
|
2019-01-16 |
2022-04-14 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human cd137 and uses thereof
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
GB201905552D0
(en)
|
2019-04-18 |
2019-06-05 |
Kymab Ltd |
Antagonists
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
SG11202112382WA
(en)
|
2019-05-07 |
2021-12-30 |
Gracell Biotechnologies Shanghai Co Ltd |
Engineered immune cell targeting bcma and use thereof
|
|
KR102503349B1
(ko)
|
2019-05-14 |
2023-02-23 |
프로벤션 바이오, 인코포레이티드 |
제1형 당뇨병을 예방하기 위한 방법 및 조성물
|
|
GB2590642B
(en)
|
2019-12-20 |
2024-02-14 |
Kymab Ltd |
Improved lambda antibodies
|
|
JP2022532388A
(ja)
|
2019-05-15 |
2022-07-14 |
カイマブ・リミテッド |
改善されたラムダ抗体
|
|
CN110272495A
(zh)
*
|
2019-06-11 |
2019-09-24 |
南京华岩生物技术有限公司 |
一种能结合两种抗原的双特异性结合的免疫球蛋白及其用途
|
|
MY206255A
(en)
*
|
2019-07-19 |
2024-12-05 |
Sinocelltech Ltd |
Humanized anti-vegf monoclonal antibody
|
|
BR112022000876A2
(pt)
|
2019-07-19 |
2022-04-26 |
Oncoresponse Inc |
Anticorpos imunomoduladores e métodos de uso destes
|
|
JP2022548484A
(ja)
|
2019-09-16 |
2022-11-21 |
サーフィス オンコロジー インコーポレイテッド |
抗ｃｄ３９抗体の組成物及び方法
|
|
TW202521984A
(zh)
|
2019-09-25 |
2025-06-01 |
美商表面腫瘤學有限責任公司 |
抗ｉｌ－２７抗體及其用途
|
|
CN113416258B
(zh)
|
2019-10-24 |
2023-08-29 |
北京免疫方舟医药科技有限公司 |
一种多特异性抗体及其制备方法和用途
|
|
WO2021101346A1
(en)
*
|
2019-11-21 |
2021-05-27 |
Dong-A St Co., Ltd. |
Anti-ror1/anti-4-1bb bispecific antibodies and uses thereof
|
|
TWI774137B
(zh)
*
|
2019-11-26 |
2022-08-11 |
大陸商上海岸邁生物科技有限公司 |
針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
|
|
TWI772984B
(zh)
*
|
2019-11-27 |
2022-08-01 |
大陸商上海岸邁生物科技有限公司 |
TGFβ/PD-L1雙特異性結合蛋白
|
|
TWI845803B
(zh)
|
2020-01-06 |
2024-06-21 |
美商法西尼克斯股份有限公司 |
抗ｃｃｒ８抗體及其用途
|
|
EP4100434A1
(en)
|
2020-02-03 |
2022-12-14 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
US11179473B2
(en)
|
2020-02-21 |
2021-11-23 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
TWI859420B
(zh)
|
2020-02-26 |
2024-10-21 |
美商維爾生物科技股份有限公司 |
抗sars-cov-2抗體及使用其之方法
|
|
EP4110818A1
(en)
|
2020-02-26 |
2023-01-04 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
|
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
|
JP2024518539A
(ja)
|
2020-04-04 |
2024-05-01 |
ジャナックス セラピューティクス，インク． |
抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法
|
|
EP4135846A1
(en)
|
2020-04-14 |
2023-02-22 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
US11661450B2
(en)
*
|
2020-04-22 |
2023-05-30 |
LBL Biotechnology Inc. |
Combination therapy using an IL-20 antagonist and an immune checkpoint inhibitor
|
|
CN113563473A
(zh)
|
2020-04-29 |
2021-10-29 |
三生国健药业（上海）股份有限公司 |
四价双特异性抗体、其制备方法和用途
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
JP2023525039A
(ja)
|
2020-05-08 |
2023-06-14 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２に対する抗体
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
CN115803343A
(zh)
*
|
2020-05-26 |
2023-03-14 |
百奥泰生物制药股份有限公司 |
多特异性抗体及其应用
|
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
CA3180477A1
(en)
|
2020-06-12 |
2021-12-16 |
Elizabeth Alexander |
Antibody therapies for sars-cov-2 infection
|
|
US20230242658A1
(en)
|
2020-06-30 |
2023-08-03 |
Nona Biosciences (Suzhou) Co., Ltd. |
4-1bb-binding protein and use thereof
|
|
WO2022002038A1
(zh)
|
2020-06-30 |
2022-01-06 |
和铂医药(上海)有限责任公司 |
免疫细胞衔接器多特异性结合蛋白及其制备和应用
|
|
JP7620780B2
(ja)
|
2020-06-30 |
2025-01-24 |
ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド |
Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質
|
|
CN116209678A
(zh)
|
2020-07-01 |
2023-06-02 |
安尔士制药公司 |
抗asgr1抗体缀合物及其用途
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
CN114085288A
(zh)
*
|
2020-08-24 |
2022-02-25 |
岸迈生物科技(苏州)有限公司 |
抗ror1抗体
|
|
EP4217385A2
(en)
|
2020-09-28 |
2023-08-02 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
|
JP2023545520A
(ja)
|
2020-10-14 |
2023-10-30 |
ビリジアン セラピューティクス， インコーポレイテッド |
甲状腺眼疾患を治療するための組成物及び方法
|
|
GB202017058D0
(en)
|
2020-10-27 |
2020-12-09 |
Kymab Ltd |
Antibodies and uses thereof
|
|
JP2023551667A
(ja)
|
2020-11-23 |
2023-12-12 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
抗－インフルエンザ抗体及びその組合せ
|
|
KR20230135569A
(ko)
|
2020-11-23 |
2023-09-25 |
비르 바이오테크놀로지, 인코포레이티드 |
인플루엔자 a 바이러스에 대한 항체
|
|
WO2022109309A1
(en)
|
2020-11-23 |
2022-05-27 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibodies against influenza neuraminidase
|
|
WO2022115486A1
(en)
|
2020-11-25 |
2022-06-02 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple betacoronaviruses
|
|
GB202101125D0
(en)
|
2021-01-27 |
2021-03-10 |
Kymab Ltd |
Antibodies and uses thereof
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
WO2022236134A1
(en)
|
2021-05-07 |
2022-11-10 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
CN117616137A
(zh)
*
|
2021-05-11 |
2024-02-27 |
佳努克斯治疗公司 |
靶向egfr和cd3的抗体及其用途
|
|
GB202107372D0
(en)
|
2021-05-24 |
2021-07-07 |
Petmedix Ltd |
Animal models and therapeutics molecules
|
|
AU2022280767A1
(en)
|
2021-05-24 |
2024-01-18 |
Humabs Biomed Sa |
Engineered polypeptides
|
|
WO2023019171A1
(en)
|
2021-08-10 |
2023-02-16 |
Viridian Therapeutics, Inc. |
Compositions, doses, and methods for treatment of thyroid eye disease
|
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
|
WO2023034866A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
|
CN113876809B
(zh)
*
|
2021-10-28 |
2025-04-29 |
安徽医科大学 |
一种表达TgMIF蛋白的巨噬细胞在制备治疗肝纤维化药物中的应用
|
|
CA3236138A1
(en)
*
|
2021-11-02 |
2023-05-11 |
Shiyong GONG |
Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
|
|
EP4444758A2
(en)
|
2021-12-10 |
2024-10-16 |
Omeros Corporation |
Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
|
|
US20250084169A1
(en)
|
2022-01-12 |
2025-03-13 |
Biomolecular Holdings Llc |
Nk/monocyte engagers
|
|
WO2023137387A2
(en)
*
|
2022-01-12 |
2023-07-20 |
Biomolecular Holdings Llc |
Tetrahedral antibodies
|
|
CN114397439B
(zh)
*
|
2022-01-14 |
2023-09-05 |
南京医科大学 |
音猬因子在制备主动脉夹层辅助诊断试剂中的应用
|
|
US20230416406A1
(en)
|
2022-03-10 |
2023-12-28 |
Omeros Corporation |
Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
|
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
|
JP2025522295A
(ja)
|
2022-05-23 |
2025-07-15 |
ヒューマブス・バイオメッド・ソシエテ・アノニム |
インフルエンザノイラミニダーゼに対する広域中和抗体
|
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
|
GB202209247D0
(en)
|
2022-06-23 |
2022-08-10 |
Petmedix Ltd |
Animal models and therapeutic molecules
|
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
EP4562034A1
(en)
|
2022-07-27 |
2025-06-04 |
Humabs Biomed SA |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
|
WO2024112818A1
(en)
|
2022-11-22 |
2024-05-30 |
Humabs Biomed Sa |
Engineered anti-sars-cov-2 antibodies and uses thereof
|
|
GB202217978D0
(en)
|
2022-11-30 |
2023-01-11 |
Petmedix Ltd |
Rodents expressing a common light chain
|
|
WO2024118998A2
(en)
|
2022-12-01 |
2024-06-06 |
Vir Biotechnology, Inc. |
Engineered anti-sars-cov-2 antibodies and methods of using the same
|
|
EP4634214A1
(en)
|
2022-12-15 |
2025-10-22 |
Aarhus Universitet |
Synthetic activation of multimeric transmembrane receptors
|
|
CR20250284A
(es)
|
2022-12-19 |
2025-08-29 |
Astrazeneca Ab |
Tratamiento de la enfermedad autoinmunitaria
|
|
WO2024131731A1
(zh)
*
|
2022-12-19 |
2024-06-27 |
和铂医药(上海)有限责任公司 |
"κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用
|
|
EP4658310A1
(en)
|
2023-01-30 |
2025-12-10 |
Kymab Limited |
Antibodies
|
|
WO2024197157A1
(en)
|
2023-03-21 |
2024-09-26 |
Biograph 55, Inc. |
Cd19/cd38 multispecific antibodies
|
|
WO2024215762A1
(en)
|
2023-04-10 |
2024-10-17 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
WO2025010424A1
(en)
|
2023-07-06 |
2025-01-09 |
Vir Biotechnology, Inc. |
Antibodies against staphylococcus antigens and methods of using the same
|
|
WO2025015321A1
(en)
|
2023-07-13 |
2025-01-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
|
WO2025158009A1
(en)
|
2024-01-26 |
2025-07-31 |
Almirall S.A. |
Bispecific molecules and methods of treatment using the same
|
|
WO2025212726A2
(en)
|
2024-04-04 |
2025-10-09 |
Compass Therapeutics, Inc. |
Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
|
|
WO2025226603A1
(en)
|
2024-04-22 |
2025-10-30 |
Surface Oncology, LLC |
Methods for treating cancer using anti-ccr8 antibodies
|
|
WO2025240781A2
(en)
|
2024-05-15 |
2025-11-20 |
Werewolf Therapeutics, Inc. |
Modified antibodies and immunoglobulin formats
|